Gilead price target lowered to $76 from $80 at Barclays

Barclays lowered the firm’s price target on Gilead to $76 from $80 and keeps an Equal Weight rating on the shares post the Q1 report. The company’s HIV zero-growth messaging for 2025 puts the onus on cell therapy and the seladelpar launch to deliver overall sales growth, the analyst tells investors in a research note.